Systematic review suggests resveratrol may improve glycemic control and protect pancreatic beta-cell function in diabetes.
This systematic review evaluates the potential metabolic and pancreatic protective effects of resveratrol in patients with type 2 diabetes mellitus and pancreatogenic diabetes. The scope encompasses experimental and clinical studies examining resveratrol's impact on glycemic control, inflammatory responses, oxidative stress, and pancreatic beta-cell function.
The authors synthesize findings indicating that resveratrol may improve glycemic control, attenuate inflammatory responses, reduce oxidative stress, and protect pancreatic beta-cell function. These conclusions are drawn from a body of evidence that includes both experimental models and clinical observations.
A key limitation noted is that direct studies investigating the role of resveratrol specifically in pancreatogenic diabetes remain scarce. The review highlights that future research specifically targeting pancreatic diseases associated with diabetes is needed to clarify the therapeutic potential of resveratrol in disorders affecting the exocrine–endocrine pancreatic axis. Consequently, the practice relevance is currently limited by the scarcity of direct clinical data in this specific population.